Phenotypic plasticity of ER+ breast cancer in the bone microenvironment
Author:
Bado Igor L., Wang Hai, Sarkar Poonam, Liu Jun, Wu William, Zhang Weijie, Lo Hin-Ching, Muscallera Aaron, Janghorban Mahnaz, Kim Ik-Sun, Singh Swarnima, Goldstein Amit, Singh Purba, Shixia Huang, Waleed Gaber M., Ellis Matthew J., Zhang Xiang H.-F.ORCID
Abstract
SummaryER+ breast cancer exhibits a strong bone-tropism in metastasis. How the bone microenvironment impacts the ER signaling and endocrine therapies remains poorly understood. Here, we discover that the osteogenic niche transiently reduces ER expression and activities specifically in bone micrometastases (BMMs), leading to endocrine resistance. This is mediated by gap junctions and paracrine FGF/PDGF signaling, which together generate a stable “memory”: cancer cells extracted from bone remain resistant to endocrine therapies for several generations. Using single cell-derived populations (SCPs), we demonstrated that this process is independent of clonal selection, and represents an EZH2-mediated epigenomic reprogramming. EZH2 drives ER+ BMMs toward a basal and stem-like state. EZH2 inhibition reverses endocrine resistance. Our data demonstrates how epigenomic adaptation to the bone microenvironment drives phenotypic plasticity of metastatic seeds and alters their therapeutic responses together with clonal selection, and provides insights into the clinical enigma of ER+ metastatic recurrences despite endocrine therapies.
Publisher
Cold Spring Harbor Laboratory
Reference73 articles.
1. Andrade, K. , Fornetti, J. , Zhao, L. , Miller, S.C. , Randall, R.L. , Anderson, N. , Waltz, S.E. , McHale, M. , and Welm, A.L. (2017). RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Sci. Transl. Med. 2. Genes that mediate breast cancer metastasis to the brain 3. Factors regulating the growth of metastatic cancer in bone. 4. Brown, D. , Smeets, D. , Székely, B. , Larsimont, D. , Marcell Szász, A. , Adnet, P.-Y. , Rothé, F. , Rouas, G. , Nagy, Z.I. , Faragó, Z. , et al. (2017). Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat. Commun. 8. 5. Campbell, J.E. , Kuntz, K.W. , Knutson, S.K. , Warholic, N.M. , Keilhack, H. , Wigle, T.J. , Raimondi, A. , Klaus, C.R. , Rioux, N. , Yokoi, A. , et al. (2015). EPZ011989, A potent, orally-available EZH2 inhibitor with robust in vivo activity. ACS Med. Chem. Lett.
|
|